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Nonstructural 5A protein (NS5A) of hepatitis C virus (HCV) is localized in the cytoplasm although it has a functional nuclear
localization signal. To clarify the determinant of NS5A cytoplasmic localization, various N- or C-terminal deleted NS5A
mutants were generated and their subcellular localization was analyzed in cell lines after transient expression. N-terminal
deleted forms of NS5A were localized in the nucleus, and the sequence of the N-terminal 27 amino acids of NS5A had
sufficient function to cause retention of a normally nuclear protein in the cytoplasm. These observations indicated that
cytoplasmic localization of NS5A is determined primarily by the N-terminal region of the molecule. In addition, we found
proteolytic processing of NS5A in transiently expressing cells. In these cells, cleavage occurred at a few sites located in the
N- and C-terminal regions of NS5A. This cleavage in cells was enhanced by apoptotic stimuli and was inhibited by the
caspase inhibitor Z-VAD-FMK, suggesting that a caspase-like protease(s) contributes to the cleavages of NS5A. Based on the
results of mutational analysis of NS5A, we predicted one cleaved form, which had lost both the N- and the C-terminal portions
of NS5A, to be composed of amino acid residues 155 to 389. Peptide containing the same amino acid sequence as this
cleaved product was localized in the nucleus. Furthermore, we found that a fusion protein consisting of Gal4 DNA-binding
domain fused with this cleaved form showed transcriptional activity only when the a-catalytic subunit of protein kinase A
(PKA) was coproduced, suggesting that the transcriptional activity of this product was regulated by PKA. These results
suggested that the cleavage product of NS5A by a caspase-like protease(s) plays a role in transcriptional regulation of the
host cell gene(s) in HCV-infected cells. © 2000 Academic PressINTRODUCTION
Hepatitis C virus (HCV) is a major causative agent of
posttransfusion non-A, non-B hepatitis. HCV is a posi-
tive-sense, single-stranded RNA virus belonging to the
third genus of Flaviviridae (Choo et al., 1991; Kato et al.,
1990; Takamizawa et al., 1991). The HCV genome has a
single open reading frame that encodes a precursor
polyprotein, and individual virus proteins are produced
from the polyprotein by host and viral protease-mediated
cleavage (Eckart et al., 1993; Grakoui et al., 1993a,b;
ijikata et al., 1991, 1993a, 1993b; Tanji et al., 1994a,b;
omei et al., 1993). The viral nonstructural 5A (NS5A)
rotein containing 447 amino acid (aa) residues is phos-
horylated mainly at serine residues located in the C-
erminal and central regions of the molecule (Asabe et
l., 1997; Kaneko et al., 1994; Hirota et al., 1999; Tanji et
al., 1995a,b). Analysis of interferon (IFN)-treated HCV-
infected patients for the viral genome revealed that
amino acid mutations in the central or the C-terminal
region of NS5A were correlated with increased sensitiv-
ity to IFN and low viral load (Duverlie et al., 1998; Eno-
moto et al., 1995, 1996; Sato and Enomoto, 1998). Re-
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476cently, Gale et al. (1997, 1998a, 1998b, 1999) reported that
activity of IFN-induced double-stranded RNA-activated
protein kinase (PKR), one of the antiviral proteins en-
coded by host cells, was repressed by NS5A through
association with an IFN sensitivity-determining region
(ISDR) located at the center of the NS5A molecule. The
N-terminal deleted forms of NS5A fused to the DNA-
binding domain of Gal4 activated transcription of a re-
porter gene driven by Gal4 in yeast and human hepa-
toma cells, suggesting that NS5A has a potent transcrip-
tional activity (Kato et al., 1997; Tanimoto et al., 1997).
Furthermore, mutations in the ISDR have been shown to
affect the transcriptional activity of NS5A (Fukuma et al.,
1998).
A previous study showed that NS5A has a functional
nuclear localization signal (NLS) sequence (PPRKKRTVV,
aa residues 354–362) that is competent to target a pro-
tein, Escherichia coli b-galactosidase, to the nucleus
when fused to its N-terminus (Ide et al., 1996). However,
the intact form of NS5A protein is localized mainly in the
cytoplasm of hepatocytes in chronically HCV-infected
patients or NS5A-expressing mammalian cells. Thus, it
remains to be clarified whether NS5A is transported from
the cytoplasm to the nucleus during the HCV replication
cycle, and the roles, if any, of this trafficking event in HCV
pathogenesis remain to be determined.
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477CLEAVAGE OF HCV NS5A BY CASPASE-LIKE PROTEASE(S)In this study, we demonstrated that the N-terminal
deleted forms of NS5A were localized in the nucleus and
the peptide with the N-terminal 27 aa residues was
sufficient to retain a nuclear protein in the cytoplasm
when fused to its N-terminus. These observations indi-
cated that the cytoplasmic localization of NS5A was
conferred by the N-terminal region of this molecule. Fur-
thermore, we found that cleavage of NS5A occurred in
NS5A-expressing cells, and the cleavage of NS5A was
enhanced by apoptotic stimuli. A peptide containing the
same amino acid sequence as one of the cleaved forms
of NS5A was localized in the nucleus and had potent
transactivating function in transiently expressing cells.
These observations highlight the function of nuclear lo-
calization of NS5A in the HCV replication cycle.
RESULTS
Subcellular localization of various NS5A mutants in
mammalian cells
We and others have shown previously that NS5A is
FIG. 1. Subcellular localization of various NS5A mutants. (A) Immunof
-tag epitope at their C-termini; i.e., full-length (5A1-447E), C-terminally
-terminally deleted form (5A163-378E). Saos-2 cells transfected with ex
ntibody, and the immunecomplexes were detected with rhodamine-co
ame cells is also shown (bottom). (B) Schematic representation of NS5
f various NS5A derivatives is shown on the right side of the figure as
ocalization. Numbers above the illustration show aa position from the N
y the solid bar. The names of the NS5A derivatives are shown on thelocalized in the cytoplasm even though it has a functionalNLS (Fipaldini et al., 1999; Ide et al., 1996; Tanji et al.,
1995b). To clarify the determinant of NS5A cytoplasmic
localization, we analyzed the subcellular localization of
various N- or C-terminal deleted NS5A mutants. We con-
structed each NS5A mutant fused with the E-tag epitope
at its C-terminus. These epitope-tagged NS5A mutants
were expressed in Saos-2 cells, and we examined the
subcellular localization of these proteins by indirect im-
munofluorescence staining with anti-E-tag antibody 24 h
after transfection. Full-length NS5A, 5A1-447, and the
C-terminal deleted form of NS5A, 5A1-378E, were local-
ized in the cytoplasm, whereas the N-terminal deleted
form and both N- and C-terminal deleted form of NS5A,
5A163-447E, or 5A163-378E, respectively, were predom-
inantly localized in the nucleus (Fig. 1A). In other exper-
iments, we found that deleting only 27 aa residues of the
N-terminus was sufficient to translocate NS5A to the
nucleus (data not shown). The subcellular localization of
each NS5A mutant is shown in Fig. 1B. These observa-
tions indicated that deleting the N-terminus of NS5A
caused localization of the protein to the nucleus. Among
ence staining of Saos-2 cells expressing NS5A mutants fused with the
form (5A1-378E), N-terminally deleted form (5A163-447E), and N- and
n plasmids for NS5A derivatives were fixed and stained with anti-E-tag
ed secondary antibodies (top). Staining of the nucleus by DAPI in the
ts derivatives and their subcellular localization. Subcellular localization
: C, predominantly cytoplasmic localization; N, predominantly nuclear
nus of NS5A. Localization of NLS in NS5A from aa 354 to 362 is shownluoresc
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478 SATOH ET AL.terminal sequences of NS5A but containing the NLS
region, was localized to the nucleus, while another form,
5A163-278E, which had a larger C-terminal deletion than
5A163-378E and lacked the NLS region, was predomi-
nantly found in the cytoplasm, suggesting that a previ-
ously identified NLS between 278 and 378 aa residues of
NS5A functions as a nuclear targeting signal of the
N-terminal deleted NS5A.
The N-terminal 27 aa residues of NS5A are sufficient
to retain a nuclear protein in the cytoplasm
The observation that the N-terminal deleted form of
NS5A was localized to the nucleus could be interpreted
in one of two ways: (1) the NLS sequence of NS5A may
be masked conformationally by its N-terminal sequence,
and thereby the recognition of the NLS sequence with a
nuclear importing factor such as importin could be inhib-
ited, or (2) the N-terminal sequence of NS5A may be a
cytoplasm retention signal (CRS) that is competent to
target a protein to the cytoplasm and is more effective
than the NLS sequence of NS5A. To verify which of these
possibilities is correct, we constructed an expression
plasmid from which a fusion protein with the sequence of
the N-terminal 27 aa residues of NS5A to the N-terminus
of HCV core mutant, Dcore151, was produced (Fig. 2A). It
has been reported that the intact core protein is localized
to the cytoplasm, while Dcore151, with deletion of the
C-terminal 40 aa residues, was localized to the nucleus
(Liu et al., 1997; Marusawa et al., 1999; Suzuki et al.,
995). The plasmid encoding this fusion protein, desig-
ated 5A1-27Dcore151, was transfected into Saos-2
ells, and the subcellular localization of this protein was
xamined by immunofluorescence using anti-core anti-
ody. Figure 2B shows that this fusion protein was local-
zed to the cytoplasm (middle), whereas Dcore151 itself
as predominantly localized to the nucleus as expected
left). This alteration of subcellular localization by fusion
f the N-terminal 27 aa residues of NS5A was specific
ince fusion of the other NS5A-derived sequence, span-
ing residues 28 to 77, to the N-terminus of Dcore151
howed no effect on subcellular localization (Fig. 2B,
ight). These results indicated that NS5A has a CRS
egion within its N-terminal 27 aa residues.
S5A is cleaved by a caspase-like protease(s)
n cells
Our results indicated that NS5A can translocate to the
ucleus if its N-terminus is removed. Thus, we examined
hether N-terminally deleted forms of NS5A could be
roduced by proteolytic processing in NS5A-expressing
ells. When NS5A was transiently produced in Saos-2
ells, proteins that migrated faster than the authentic
6-kDa NS5A protein were detected by the anti-NS5A
ntibody (Fig. 3, lane 2). Furthermore, we observed that,espite a decrease in the 56-kDa NS5A protein level, two
ands of 48 and 31 kDa were both enhanced in a time-
ependent manner after exposure to apoptotic stimuli
uch as tumor necrosis factor-a (TNF-a) plus cyclohexi-
mide (CHX) or poly(I–C) plus CHX (Fig. 3, lanes 2 to 6;
and data not shown). In addition, we observed that pro-
cessing of the authentic NS5A protein was suppressed
by pretreatment with the caspase inhibitor carbobenzo-
xy-L-valyl-L-alanyl-L-b-methyl-aspart-1-yl-fluoromethane
(Z-VAD-FMK) before the addition of an apoptotic stimulus
(Fig. 3, lane 7). These phenomena were also observed in
HeLa and HepG2 cells (data not shown). These obser-
vations suggested that the NS5A protein was cleaved in
the cells by a caspase-like protease(s) and the resulting
processed products accumulated in the cells. We tried to
confirm the processing of NS5A in cells expressing the
entire HCV polyprotein. However, production of NS5A
from the entire HCV polyprotein was too low for its
processing to be analyzed. Thus, it is necessary to de-
velop an efficient protein expression system to analyze
FIG. 2. The sequence of the N-terminal 27 aa residues of NS5A
functions as a cytoplasm retention signal. (A) Saos-2 cells were trans-
fected with plasmids expressing three types of Dcore151 derivative; i.e.,
Dcore151 itself, Dcore151 fused at its N-terminus with the sequence
from aa 1 to 27 of NS5A (5A1-27Dcore151), and Dcore151 fused at its
N-terminus with the sequence from aa 28 to 77 of NS5A (5A28-
77Dcore151). The lysates of Saos-2 cells were fractionated by SDS–15%
PAGE followed by blotting analysis using the anti-core antibody. (B)
Immunofluorescence staining of Saos-2 cells expressing Dcore151
fusion proteins. Saos-2 cells transfected with plasmids expressing
proteins denoted above each panel were fixed and stained with anti-
core antibody, and the immunecomplexes were detected with rhoda-
mine-conjugated secondary antibodies (top). The staining of the nu-
cleus by DAPI in the same cells is also shown (bottom).NS5A processing.
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479CLEAVAGE OF HCV NS5A BY CASPASE-LIKE PROTEASE(S)Presence of multiple cleavage sites for caspase-like
protease(s) in NS5A
The anti-NS5A antibody used in this study recognizes
the region from aa residues 228 to 278 in NS5A (Fig. 4A).
To determine the cleavage site(s), we expressed NS5A
tagged at its N- or C-terminus with a marker peptide in
Saos-2 cells. Then, the cells were treated with CHX in the
presence or in the absence of TNF-a for 8 h. Cell lysate
was prepared and analyzed for NS5A protein using the
anti-NS5A antibody or antibodies against each tag. When
NS5A protein tagged with green fluorescent protein
(GFP) at its C-terminus, 5A-GFP (83 kDa), was produced
in Saos-2 cells, an 83-kDa protein of the expected size
from the amino acid composition of the fusion protein
was produced. Cleaved forms of 48 and 31 kDa were
detected by the anti-NS5A antibody, and production of
the cleaved forms was enhanced by treatment with
TNF-a (Fig. 4B, top, lanes 5 and 6). Importantly, cleaved
roducts with the same molecular masses were also
etected when authentic NS5A was produced in Saos-2
ells (Fig. 4B, top, lanes 3 and 4). Thus, it was suggested
hat these two cleaved products were produced by cleav-
ge at least in the C-terminal region of NS5A. Further-
ore, in 5A-GFP-expressing cells, a 35-kDa protein
about 8 kDa larger than the parent GFP) was detected
y anti-GFP antibody (Fig. 4B, bottom, lanes 5 and 6),
uggesting that the C-terminal cleavage site is located
lose to 70 aa residues from the C-terminus of NS5A.
When NS5A protein tagged with FLAG at its N-termi-
us, FLAG-5A, was produced in Saos-2 cells, 50- and
1-kDa cleaved forms of FLAG-5A in addition to the
roduct of the expected size (58 kDa) were mainly de-
FIG. 3. Cleavage of NS5A in Saos-2 cells by caspase-like pro-
tease(s). Saos-2 cells transfected with a control expression plasmid
pKS(1)/CMV (lane 1) or NS5A expression plasmid pCMV/5A1-447
(lanes 2 to 7) were pretreated with (lane 7) or without (lanes 1 to 6) 50
mM Z-VAD-FMK for 1 h and then treated with 10 ng/ml TNF-a plus 50
mg/ml CHX for the times indicated above panel. The cell lysates were
fractionated by SDS–10% PAGE followed by Western blotting using the
anti-NS5A antibody. NS5A (56 kDa) and apoptosis-enhanced cleavage
products of NS5A, 48- and 31-kDa products, are shown on the right with
arrows. The positions of molecular mass markers (in kilodaltons) are
shown on the left.ected by the anti-NS5A antibody (Fig. 4B, top, lane 7 and o). The 50-kDa protein was about 2 kDa larger than the
leaved product of 48 kDa, which was observed in cells
xpressing authentic NS5A. This 50-kDa protein was
etected by anti-FLAG antibody (Fig. 4B, bottom, lanes 7
nd 8), indicating that its N-terminus reflects that of
LAG-5A. As a 31-kDa protein of the FLAG-5A derivative
as recognized by the anti-NS5A antibody but not by the
nti-FLAG antibody (Fig. 4B, top and bottom, lanes 7 and
), it was estimated to be the N-terminally cleaved form
f FLAG-5A. Furthermore, in FLAG-5A-expressing cells, a
9-kDa cleaved form was detected by anti-FLAG anti-
ody (Fig. 4B, bottom, lanes 7 and 8), suggesting that it
as produced by cleavage close to 150 aa residues from
he N-terminus of authentic NS5A. In addition, we ob-
erved the production of a 32-kDa cleaved form of
LAG-5A, which was recognized by anti-FLAG antibody
ut not by the anti-NS5A antibody (Fig. 4B, top and
ottom, lanes 7 and 8), indicating that an additional
leavage site in FLAG-5A was located 270 aa residues
rom the N-terminus of the authentic NS5A. Failure to
etect the C-terminal half of FLAG-5A produced by cleav-
ge close to 270 aa by the anti-NS5A antibody might
ave been due to destruction of the epitope for the
nti-NS5A antibody used in this study, because the
pitope for this antibody was estimated to be localized in
he region surrounding the cleavage site. A 31-kDa pro-
ein was detected by the anti-NS5A antibody in cells
xpressing authentic NS5A as well as the N- or C-
erminally tagged NS5A derivative but was not detected
y the antibodies for each tag, suggesting that the 31-
Da protein was an N- and C-terminally cleaved form of
S5A.
These observations suggested that NS5A is cleaved at
t least three sites. As cleavage at these sites was not
fficient, several cleaved products were expected to be
roduced. One cleavage site may be located in the
ossible epitope region for the anti-NS5A antibody. Thus,
eptides having this cleaved site at the N- or C-terminus
ay not be recognized by the antibody. Peptides that do
ot have the epitope sequence also are not recognized
y the antibody. Thus, only a few cleaved products of
S5A could be detected by the anti-NS5A antibody.
We detected a 41-kDa fragment in NS5A- and 5A-GFP-
xpressing cells and a larger form of 2 kDa in FLAG-5A-
xpressing cells by the anti-NS5A antibody (Fig. 3, lane
, and Fig. 4B, top, lanes 3, 5, and 7). Furthermore, a faint
and of a 43-kDa fragment in FLAG-5A-expressing cells
as detected by anti-FLAG antibody when the film for
estern blotting was exposed for a long period (data not
hown). These data indicated that the 41-kDa fragment
etected by the anti-NS5A antibody in NS5A-expressing
ells contained the N-terminal portion of NS5A. However,
t is not yet clear how this molecule is produced in
S5A-expressing cells. We also observed that the level
f this fragment was decreased with time after apoptotic
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480 SATOH ET AL.stimulus (Fig. 3, lanes 2 to 6), suggesting that it was
proteolytically processed during apoptosis.
Mapping of the caspase cleavage sites in NS5A
The above results suggested that there are at least
three caspase-mediated cleavage sites in NS5A. To de-
termine these cleavage sites, we examined production of
cleavage products from mutagenized NS5A derivatives
at the likely sites for caspase recognition. Since the
above observations suggested that one cleavage site
was located close to 150 aa residues from the N-termi-
nus, we surveyed the amino acid sequence surrounding
this position of NS5A for an appropriate caspase cleav-
age motif. We found an Asp residue at position 154 as a
potential cleavage site for caspases (Thr-Glu-Leu-Asp154/
Gly). To verify that this position was indeed one of the
cleavage sites in NS5A, we constructed a plasmid to
produce the mutant form of FLAG-5A by replacing Asp at
this position with Glu and designated this protein FLAG-
FIG. 4. Cleavage of N- or C-terminally tagged form of NS5A by casp
he C-terminus with green fluorescent protein (5A-GFP), and NS5A tag
epresentation for 5A indicates the region of the epitope for the anti-NS5
f the epitope. (B) Saos-2 cells transfected with a control expression pla
bove panel, were treated with 50 mg/ml CHX in the presence (1) or in
y SDS–PAGE followed by blotting using the anti-NS5A antibody (top
ositions of NS5A, 5A-GFP, FLAG-5A, and apoptosis-enhanced cleavag
in kilodaltons) are shown on the left of each panel.5AD154E. When FLAG-5AD154E was produced tran- rsiently in Saos-2 cells, the 31-kDa cleaved form, as seen
in Saos-2 cells producing FLAG-5A, was not detected by
the anti-NS5A antibody even after apoptotic stimulation
(Fig. 5, top, lanes 5 and 6). Furthermore, the 19-kDa
cleaved form of FLAG-5A was not detected by anti-FLAG
antibody, while the 50- and 32-kDa cleaved forms were
detected (Fig. 5, bottom, lanes 5 and 6). These observa-
tions indicated that the position at Asp154/Gly in NS5A is
ne of the cleavage sites targeted by the caspase-like
rotease(s) and Gly155 is likely to be the N-terminus of the
1-kDa protein recognized by the anti-NS5A antibody. In
omparison with FLAG-5A-producing cells, the 50-kDa
leaved product recognized by both anti-NS5A and anti-
LAG antibodies accumulated to higher levels in FLAG-
AD154E-producing cells, suggesting that this 50-kDa
rotein was the intermediate in production of the 31-kDa
rotein.
Based on the results shown in Fig. 4B, the C-terminal
leavage site was estimated to be located close to 70 aa
protease(s). (A) Schematic representations of NS5A, NS5A tagged at
the N-terminus with FLAG peptide (FLAG-5A). The top bar above the
ody, and numbers 228 and 278 show the N- and C-terminal aa residues
KS(1)/CMV (vect.) or NS5A derivative expression plasmids, as denoted
sence (2) of 10 ng/ml TNF-a for 8 h. The cell lysates were fractionated
FP antibody (bottom, left), or anti-FLAG antibody (bottom, right). The
ucts are shown on the right with arrows. The molecular mass markersase-like
ged at
A antib
smid p
the ab
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481CLEAVAGE OF HCV NS5A BY CASPASE-LIKE PROTEASE(S)residue at position 389 as a potential cleavage site for
caspases (Ser-Ala-Val-Asp389/Ser). When the mutant form
of FLAG-5A, FLAG-5AD389E, in which Glu at position 389
was substituted for Asp, was produced in Saos-2 cells
with or without TNF-a treatment, a 39-kDa cleaved form
was detected by the anti-NS5A antibody, but 50- and
31-kDa cleaved forms, as seen in FLAG-5A, were not
detected by the anti-NS5A antibody (Fig. 5, top, lanes 7
and 8). In this mutant, however, generation of the 19- and
32-kDa cleaved forms detected by anti-FLAG antibody
was not affected (Fig. 5, bottom, lanes 7 and 8). These
observations showed that the C-terminal cleavage site in
NS5A is located at position Asp389/Ser, and Asp389 is
likely to be the C-terminus of the 50- and 31-kDa cleaved
forms of FLAG-5A. Thus, the 31-kDa cleaved form of
NS5A was likely to encode the residues from aa 155 to
389, containing the NLS region. When a protein of 5A155-
389 corresponding to the 31-kDa cleaved form of NS5A
was produced in Saos-2 cells, it was shown to be local-
ized in the nucleus as expected (data not shown).
We found that in the series of FLAG-5A-expressing
FIG. 5. Mapping the cleavage sites in NS5A. Saos-2 cells transfecte
expression plasmids, as denoted above panel, were treated as descri
PAGE (top) or SDS–15% PAGE (bottom), followed by blotting using anti
full-length FLAG-5A mutants and apoptosis-enhanced cleavage prod
apoptosis-enhanced cleavage products. The molecular mass markerscells treated with TNF-a, a slower migrating band of the c2-kDa fragment derived from FLAG-5A and FLAG-
AD389E, but not from FLAG-5AD154E, was detected by
nti-FLAG antibody (Fig. 5, bottom, lanes 4, 6, and 8). It is
ossible that mobility of the 32-kDa protein may be
ffected by modification such as phosphorylation after
NF-a treatment. However, such a modification might not
ffect the change in mobility of the mutated form of the
2-kDa protein derived from FLAG-5AD154E.
he 31-kDa cleaved product of NS5A showed
nhanced transcriptional activation when the
a-catalytic subunit of PKA was coproduced
Previously, it was reported that the fusion protein con-
sisting of Gal4 DNA-binding domain (Gal4-dbd) and the
N-terminal deleted NS5A showed a transcriptional acti-
vation effect in hepatoma cells on the reporter gene that
contains Gal4 DNA sequences in the promoter (Kato et
l., 1997). We examined whether the 31-kDa cleaved
roduct of NS5A encoding residues from aa 155 to 389
ad such an activity in HepG2 cells. Gal4-5A155-389,
a control expression plasmid pKS(1)/CMV (vect.) or FLAG-5A mutant
the legend to Fig. 4B. The cell lysates were fractionated by SDS–10%
antibody or anti-FLAG antibody, respectively. The positions of 58-kDa
e shown on the right with arrows. Open circles in panels indicate
daltons) are shown on the left.d with
bed in
-NS5Aonsisting of Gal4-dbd and the residues from aa 155 to
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482 SATOH ET AL.389 of NS5A derived from the HCV clone used through-
out this experiment, was localized in the nucleus (data
not shown) and showed a weak transcriptional activation
effect (Fig. 6A, top). Such weak activity was also ob-
served when the NS5A sequence from another clone of
HCV (designated NS5A-NK) derived from the serum of a
53-year-old female patient with HCV type 1b chronic
active hepatitis (Kato et al., 1997) was used (Fig. 6A,
bottom). The transcriptional activity of Gal4-5A155-389
seemed to be saturated because changes in the expres-
sion level of this protein did not alter the activity (data not
shown).
Since the activities of some transcription factors are
regulated by phosphorylation and NS5A is phosphory-
lated in vitro by the a-catalytic subunit of PKA (Ide et al.,
1997), we investigated whether transcriptional activation
of NS5A was regulated by PKA. When Gal4-dbd-contain-
ing NS5A derivatives were coexpressed with the a-cat-
FIG. 6. Analysis of transcriptional activity of NS5A and its derivative
plasmid (pM plasmids) and a reporter plasmid, pFR-Luc, with (B) or wit
activities of cells producing NS5A or its derivatives are shown relative
is described under Materials and Methods.lytic subunit of PKA in HepG2 cells, Gal4-5A155-389 ahowed strong transcriptional activation, although the
ull-length NS5A showed no activation (Fig. 6B). These
esults suggested that the potential transcriptional activ-
ty governed by the portion from aa 155 to 389 of NS5A is
uppressed under normal conditions but this suppres-
ion can be released by proteolytic cleavage followed by
hosphorylation mediated by PKA. The different levels of
ranscriptional activity of Gal4-5A155-389 derived from
ifferent isolates of HCV seemed to reflect their charac-
eristic features and were not dependent on expression
evel (data not shown).
DISCUSSION
We and others have shown that HCV NS5A protein is
ocalized in the cytoplasm or perinucleoplasm but not in
he nucleus although NS5A contains a functional NLS
equence (PPRRKRTVV) that is present in the region from
2 cells were cotransfected with each Gal4-fusion protein expression
) pFC-PKA, which expresses the a-catalytic subunit of PKA. Luciferase
rol cells (pM-transfected cells). The structure of plasmids in this figures. HepG
hout (Aa 354 to 362, proximal to the C-terminus (Fipaldini et al.,
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483CLEAVAGE OF HCV NS5A BY CASPASE-LIKE PROTEASE(S)1999; Ide et al., 1996; Tanji et al., 1995b). In this study, we
found that N-terminally deleted forms of NS5A, with de-
letion of at least 27 aa residues, were localized predom-
inantly in the nucleus, but deletion of the NLS region from
this mutant resulted in localization in the cytoplasm.
Furthermore, we clearly showed that the 27 aa of the
N-terminus of NS5A functions as a CRS by demonstrat-
ing that a nuclear localizing protein, Dcore151, was re-
tained in the cytoplasm when fused with the N-terminal
27 aa residues of NS5A at the N-terminus of this protein.
These results suggested that the function of the N-ter-
minus CRS is dominant over that of the NLS located in
the C-terminal region, and thereby full-length NS5A is
localized in the cytoplasm. However, it is not known how
CRS determines the subcellular localization of NS5A.
Recently, Tu et al. (1999) reported that NS5A directly
interacted with human vesicle-associated membrane
protein-associated protein of 33 kDa (hVAP-33). It is in-
teresting to examine whether the N-terminal CRS region
of NS5A interacts with hVAP-33 and this interaction con-
tributes to cytoplasmic, in particular, perinucleoplasmic
localization of NS5A. To clarify the mechanism of cyto-
plasmic retention of NS5A, the physiochemical proper-
ties of the CRS sequence as well as screening for mol-
ecules that interact with CRS in cells may be required.
We showed that NS5A was cleaved by a caspase-like
protease(s) at a few sites in cells and at least two
cleaved forms of NS5A, one with a C-terminal deletion
and the other with both N- and C-terminal deletions,
were detected by the anti-NS5A antibody that recognizes
an epitope spanning aa 228 to 278. A 41-kDa fragment
containing the N-terminal portion of NS5A was also de-
tected by the anti-NS5A antibody in NS5A-expressing
cells, suggesting that a cleavage site is located close to
aa residue 350. No appropriate caspase recognition
sites were seen around this position, and thus this frag-
ment was proteolytically produced independent of
caspase.
Based on the results of the mutagenesis study, we
defined two possible cleavage sites mapped between
Asp154 and Gly155 and between Asp389 and Ser390. We did
not define the third cleavage site localized in the region
from aa 228 to 278. For two cleaved proteins detected by
the anti-NS5A antibody, we speculated that the C-termi-
nally deleted form encodes residues aa 1 to 389, and the
N- and C-terminally deleted form encodes residues aa
155 to 389. The N- and C-terminally cleaved form, des-
ignated 5A155-389, carries the NLS. In fact, it was shown
to be localized in the nucleus when transiently ex-
pressed in Saos-2 cells (data not shown). NS5A ap-
peared to be cleaved by a caspase-like protease(s), and
then some of the cleavage products were translocated to
the nucleus. Since cleavage at each site seemed to be
relatively inefficient, partially cleaved forms are expected
to accumulate in NS5A-producing cells. However, the
C-terminal fragment cleaved only at Asp154/Gly, with an Nxpected size of 39 kDa, was rarely detected by the
nti-NS5A antibody in NS5A-expressing cells, suggest-
ng that cleavage at Asp389/Ser or at the site in the region
of the epitope for the anti-NS5A antibody may be pre-
ferred by the caspase-like protease(s) rather than the
site at Asp154/Gly. Since the 31-kDa protein contained the
cleavage site at the region in the epitope, it is likely that
cleavage at Asp389/Ser occurs with the highest priority.
ecently, Lohman et al. (1999) reported a small amount of
S5A protein staining in the nucleus in a hepatoma cell
ine transfected with subgenomic HCV type 1b RNA. We
ttempted to detect nuclear localization of NS5A in
S5A-expressing Saos-2 or HepG2 cells with or without
poptotic stimulus. However, the amounts of NS5A lo-
alized to the nucleus were too low to be detected by
mmunofluorescence using our NS5A antibody in these
ell lines.
As shown in Fig. 7, the amino acid residue of Asp154 is
ell conserved and residues around Asp154 are highly
conserved among HCV isolates. However, Asp389 was
conserved only in HCV type 1b. Thus, it appears that
cleavage at Asp154/Gly is common to all HCV isolates, but
hat at Asp389/Ser occurs specifically in HCV type 1b.
hen Asp389 of HCV-1b NS5A was replaced with Glu,
leavage did not occur at this site (Fig. 5, lanes 7 and 8).
owever, the N-terminal deleted form was produced by
leavage at Asp154/Gly, suggesting that cleavage at
sp389/Ser is not essential for nuclear localization of
FIG. 7. Alignment of amino acid sequences surrounding the cleavage
sites in NS5A. The amino acid residues surrounding Asp154 and Asp389
are aligned with the sequences of various HCV strains: type 1b HCV-JT,
type 1b HCV-J, type 1b HCV-J4, type 1a HCV-J1, type 1a HCV-1, type 1a
HCV-H, type 2a HCV-J6, and type 2b HCV-J8. Residues identical to those
of HCV-JT at the given position are shown in boldface. The positions of
residues 154 and 389 are indicated by arrows.S5A. Thus, it is likely that nuclear localization of NS5A
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cleavage at Asp154.
Although the function of NS5A has not been fully
clarified, NS5A is known to be phosphorylated (Kaneko
et al., 1994; Tanji et al., 1995b), to suppress interferon-
induced double-stranded RNA-dependent protein kinase
(Gale et al., 1997, 1998a, 1998b, 1999), and to regulate the
antiviral activity of IFN (Polyak et al., 1999; Song et al.,
1999). It has also been shown that the C-terminal domain
of NS5A contains a transcriptional transactivating func-
tion (Kato et al., 1997; Tanimoto et al., 1997). These
observations suggested that NS5A plays some role in
viral replication through these functions. We confirmed
the transcriptional activation by Gal4-5A163-359 of a re-
porter gene with the Gal4 DNA sequence in its promoter
as reported by Kato et al. (1997). However, we observed
very weak transcriptional activation by Gal4-5A155-389,
in which the entire amino acid sequence of the 31-kDa
protein, the N- and C-terminal cleaved product of NS5A,
was present (Fig. 6A). Importantly, Gal4-5A155-389
showed significant transactivating function when ex-
pressed along with the a-catalytic subunit of PKA (Fig.
B), suggesting that the transcriptional activity of 5A155-
89 was activated by PKA-mediated phosphorylation. In
ddition, we observed that the activity of 5A163-359, in
hich 8 and 30 aa were truncated from the N- and
-termini of 5A155-389, respectively, was also enhanced
y the presence of PKA, indicating that there may be a
echanism for PKA-mediated enhancement of transcrip-
ional activation by NS5A. It has been shown that NS5A
as phosphorylated by the a-catalytic subunit of PKA in
vitro (Ide et al., 1997). It is interesting to note that at least
five consensus PKA phosphorylation sequence motifs,
RXS/T* and RXXS/T* (where X is any amino acid residue
and the asterisk denotes that the residue is phosphory-
lated), are present in the region spanning aa 155 to 389.
To clarify the mechanism of PKA-mediated transcrip-
tional activation, it is important to determine whether
5A155-389 is indeed phosphorylated by PKA in vivo, and,
if any, the target amino acid for PKA phosphorylation in
5A155-389. Association of NS5A with DNA is not ob-
served. Thus, it is unclear how NS5A cleavage products
play a role in regulating transcriptional activity of cellular
genes. It is possible that NS5A interacts with a cellular
transcription factor, and this interaction may be involved
in the regulation of gene expression.
We observed that the fusion protein consisting of
Gal4-dbd and full-length NS5A was localized in the cy-
toplasm but not in the nucleus (data not shown), which
may be one of the reasons that the full-length NS5A did
not show transcriptional activation irrespective of ex-
pression of the a-catalytic subunit of PKA.
We examined the effect of NS4A, which is shown to be
important for hyperphosphorylation of NS5A (Kaneko et
al., 1994), on the cleavage of NS5A and Gal4-5As-depen-
dent transcriptional activity. However, coproduction of sNS4A did not affect them even in the presence or in the
absence of PKA (data not shown). We are currently in-
vestigating the effect of other HCV proteins.
In this study we showed that NS5A was cleaved by a
caspase-like protease(s) and the peptide containing the
same amino acid sequence as one of the cleaved prod-
ucts, 31-kDa protein, was localized in the nucleus. How-
ever, the physiological roles of the modification of NS5A
such as cleavage and resultant changes in subcellular
localization of NS5A in HCV replication as well as patho-
genic roles in liver dysfunction remain to be clarified.
Previously, it was shown that NS5A is anti-apoptotic
(Gale et al., 1999). It is likely that the proteolytically
roduced 31-kDa fragment contributes to anti-apoptotic
unction of NS5A through trans-activation of an anti-
poptotic gene, like hsp70 (Ja¨a¨ttela¨ et al., 1998), which
functions downstream of the caspase(s). To clarify the
role of NS5A or the cleaved products, we are currently
investigating its effect on apoptosis. Gale et al. (1999)
also reported that suppression of PKR activity is required
for the oncogenic properties of NS5A, but NS5A has
growth-stimulatory potential that is independent of the
ability to regulate PKR. Furthermore, Ghosh et al. (1999)
reported that NS5A modulates cell cycle regulatory
genes, such as p21WAFI and the human proliferating cell
uclear antigen gene, and promotes cell growth. The
1-kDa fragment of NS5A, a potent transcriptional acti-
ator that is localized to the nucleus, was also detected
n NS5A-expressing cells without apoptotic stimulus (Fig.
, lane 2), suggesting that the 31-kDa fragment of NS5A
s produced irrespective of apoptotic induction and func-
ions as a potent transactivator under physiological con-
itions of HCV infection. Thus, it may be interesting to
nvestigate whether this fragment affects cell growth
rrespective of apoptosis. Screening for cellular target
enes of NS5A is necessary to clarify the roles of tran-
criptional activation of NS5A in the HCV replication
ycle.
MATERIALS AND METHODS
onstruction of plasmids
Construction of plasmids pCMV/5A1-447 (designated
CMV/N1973-2419 in Kaneko et al., 1994), pCMV/5A1-
47E (Hirota et al., 1999), pCMV/5A1-378E (Hirota et al.,
999), pCMV/5A163-447E (designated pCMV/N2135-
419E in Asabe et al., 1997), and pCMV/5A28-447E (des-
gnated pCMV/N2000-2419E in Asabe et al., 1997) were
eported previously. The plasmids pCMV/5A163-378E
nd pCMV/N163-278E were constructed by inserting the
stI–EcoRI fragment of PCR products amplified using
CMV/5A1-447 as a template with the sense primer,
9-AAACTGCAGCCATGCCGGCGTGCAGACCT-39, and
ntisense primer, 59-CCGGAATTCCTTAGTAGCCAGCTC-
GC-39, or 59-CCGGAATTCCTCCTTATTCTCTGA-39, re-
pectively, into the PstI–EcoRI site of pCMV/C-E-tag
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485CLEAVAGE OF HCV NS5A BY CASPASE-LIKE PROTEASE(S)(Asabe et al., 1997). The plasmid pCMV/5A155-389E was
onstructed by inserting the PstI–EcoRI fragment of the
PCR product amplified using pCMV/5A1-447 as a tem-
plate with the sense primer, 59-AAAACTGCAGCCAT-
GGGGGTGCGGTTGCACAGG-39, and antisense primer,
59-CCGGAATTCGTCAACGGCCGACGATCC-39, into the
PstI–EcoRI site of pCMV/C-E-tag. The plasmid pCMV/
5A1-149E was obtained by removing the EcoRI fragment
of pCMV/5A1-447E followed by re-ligation. Construction
of the plasmid pCMV/Dcore151 encoding a C-terminal 40
aa deleted HCV core protein was reported previously
(Marusawa et al., 1999). To obtain the plasmid pCMV/
A1-27Dcore151 or pCMV/5A28-77Dcore151, the PstI–
amHI fragment of the PCR product amplified using
CMV/5A1-447 as a template with the primer combina-
ions 59-AAACTGCAGCCATGTCCGGCTCGTGGCTAAG-
-39 and 59-CGCGGATCCGAGCTTGGACTGGAGCCA-39
r 59-AAACTGCAGCCATGCTGCCGAAATTGCCG-39 and
9-CGCGGATCCAGGCCCAACGATCCTCAT-39, respec-
ively, was inserted into the PstI–BamHI site of pCMV/
core151. The resultant plasmids, pCMV/5A1-27D-
ore151 and pCMV/5A28-77Dcore151, encoded Dcore151
used at its N-terminus with the NS5A-derived residues
onsisting of aa 1 to 27 or aa 28 to 77, respectively. The
lasmid pCMV/5A-GFP, expressing NS5A protein tagged
ith GFP at its C-terminus, was constructed as follows.
he GFP fragment obtained by digestion of pQBI25
TaKaRa) with NheI and EcoRI was filled in with Klenow,
nd the resulting fragment was then ligated with the
ragment of pCMV/5A1-447E prepared by digestion with
laI and BamHI followed by filling in the ends with
lenow. The plasmid pCMV/FLAG-5A, expressing NS5A
rotein tagged with the FLAG epitope at its N-terminus,
as constructed by inserting an annealed oligo DNA
ragment (sense, 59-TCGAAGAGCTCCACCATGGACTA-
AAGGACGACGATGACAAGC-39, and 59-TCGAGCTTGT-
ATCGTCGTCCTTGTAGTCCATGGTGGAGCTCT-39) into
he XhoI site of pCMV/5A1-447. To obtain mutant forms of
LAG-5A replacing Asp with Glu at residue 154 or 389,
esignated FLAG-5AD154E or FLAG-5AD389E, respec-
ively, two-step PCR using pCMV/5A1-447 as a template
as performed. In the first-step PCR, products desig-
ated D154E-C and D389E-C were obtained with the
ollowing combinations of sense and antisense primers:
154E-C, 59-ACTGAACTCGAGGGGGTGCGGTTGCAC-39
nd 59-TCACTGCATTCTAGTTGTGG-39; D389E-C, 59-TCG-
CCGTTGAGCTCGGCACGGCGACCGCC-39 and 59-
CACTGCATTCTAGTTGTGG-39. 5AD154E and 5AD389E
ere obtained by second-step PCR using combinations
f the primer 59-AAACTGCAGCCATGTCCGGCTCGTG-
CTAAGG-39 and D154E-C, and D389E-C, respectively.
he resultant products, 5AD154E and 5AD389E, were
igested with PstI and AccI and then exchanged with the
stI–AccI fragment of pCMV/FLAG-5A to obtain pCMV/
LAG-5AD154E and pCMV/FLAG-5AD389E, respectively.To generate a Gal4-dbd/NS5A fusion protein in cells,he PCR products amplified using pCMV/5A1-447 or pM-
S5A/F5-R5 (Kato et al., 1997) (a gift from N. Kato, con-
sisting of full-length NS5A derived from the serum of a
53-year-old male patient with HCV type 1b chronic active
hepatitis) as a template were inserted into the BamHI–
HindIII site of pM (Clontech), which expresses N-termi-
nal Gal4-dbd fusion protein in mammalian cells. pM/5A1-
447, pM/5A155-389, and pM/5A163-359 were obtained
using pCMV/5A1-447 as a template with primers F1 and
R1, F2 and R2, and F3 and R3, respectively. pM/5A155-
389(NK) and pM/5A163-359(NK) were obtained using
pM-NS5A/F5-R5 as a template with primers F2 and R2
and primers F3(NK) and R3, respectively. Nucleotide
sequences of each primer were as follows: F1, 59-
GCGGATCCGTTCCGGCTCGTGGCTAAGG-39; F2, 59-
CGCGGATCCGTGGGGTGCGGTTGCACAGG-39; F3, 59-
CGCGGATCCGTCCGGCGTGCAAACCTCTT-39; F3(NK),
59-CGCGGATCCGTCCGGCGTGCAGACCTCTC-39; R1, 59-
CCCAAGCTTTTAGCAGCAGACGATGTCGTC-39; R2, 59-
CCCAAGCTTTTAGTCAACGGCCGACGATCC-39; and R3,
59-CCCAAGCTTTTACCTCTTTCTCCGTGGAGG-39.
Cell culture
Human osteosarcoma-derived Saos-2 cells and hu-
man hepatoblastoma-derived HepG2 cells were grown
in Dulbecco’s modified Eagle’s medium supplemented
with glutamine and 10% fetal bovine serum. For stimula-
tion of apoptosis, transfected Saos-2 cells were incu-
bated for the times shown in the figures with 10 ng/ml
TNF-a (Sigma) and 50 mg/ml CHX. The caspase inhibitor
Z-VAD-fmk (Peptide Institute, Inc.) was added to cells at
50 mM 1 h before treatment with TNF-a. Poly(I–C) was
dded at 100 mg/ml with 50 mg/ml CHX for 8 h.
Transfection and protein detection
Cells were transfected with pCMV-derived plasmids
using FuGENE 6 Transfection Reagent (Boehringer). Ex-
pression of proteins derived from plasmids in cells was
examined by SDS–PAGE followed by Western blotting
analysis as described previously (Satoh et al., 1999). The
antibodies used in this experiment were anti-NS5A anti-
body (Hijikata et al., 1993b), anti-core antibody (515S,
provided by Dr. Michinori Kohara, The Metropolitan In-
stitute of Medical Science, Tokyo, Japan), anti-E-tag an-
tibody (Promega), anti-Aequorea victoria GFP antibody
(Molecular Probes), and anti-FLAG antibody (Sigma).
Immunofluorescence
Saos-2 cells were fixed with methanol:acetone (1:1).
After fixation, cells were blocked in PBS containing 0.2%
bovine serum albumin (Sigma) for 30 min and incubated
with anti-NS5A antibody or anti-E-tag antibody for 45 min.
After being washed with PBS, the cells were incubated
with rhodamine-conjugated secondary antibody and
49,6-diamidino-2-phenylindole (DAPI). After being
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486 SATOH ET AL.washed, the samples were mounted on glass slides and
observed by fluorescence microscopy.
Transcriptional activation assay
HepG2 and Saos-2 cells were used in this assay. The
reporter gene plasmid, pFR-Luc (Stratagene), possess-
ing five Gal4-DNA-binding sites following the luciferase
gene, was cotransfected with each pM expression plas-
mid in the presence or in the absence of pFC-PKA plas-
mid, which expresses the a-catalytic subunit of PKA
Stratagene). The cells were harvested at 24 h after
ransfection, and luciferase activity was quantified using
commercial kit according to the manufacturer’s proto-
ol (Promega). The efficiency of transfection was moni-
ored by cotransfection of pRL-TK plasmid, expressing
enilla luciferase (Promega). All assays were repeated
hree times, and the luciferase activity was expressed as
he mean of relative values over that of pM.
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